BIOEOTCPharmaceutical PreparationsFiscal year ends December 31
Bio Essence Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.42+0.03 (+7.72%)
Close on Oct 19, 2026
- Market cap
- $21.38M
- P/E (TTM)
- 10.5
- Dividend yield
- –
Share price
+$0.3514 (+511.5%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Bio Essence Corp grew revenue 416.6% to $2.91M over the twelve months to Jun 30, 2026.
Revenue
$2.91M
+416.6% vs. a year earlier
Operating income
$1.54M
TTM Q2 2026
EPS, diluted
$0.04
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $21.38M
- P/E ratio
- 10.5
- Price to sales
- 7.34
- Price to book
- 9.13
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $2.91M
- Net income
- $1.52M
- EPS, diluted
- $0.04
- Book value per share
- $0.05
- Diluted shares
- 51M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$2.91M+416.6% YoY
Gross profit
$2.03M+438.0% YoY
Operating income
$1.54M
Net income
$1.52M
EPS, diluted
$0.04
Free cash flow
–
Reported periodTrailing twelve months